FENNEC PHARMACEUTICALS INC
Reported by THE BANK OF NEW YORK MELLON CORPORATION
Reported 68,724 shares, up 20,602 (42.8%) from the prior quarter.
Reported value -21.5%; share count 42.8% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2023-06-30 | 399483 |
| 2023-09-30 | 347950 |
| 2023-12-31 | 516038 |
| 2024-03-31 | 535112 |
| 2024-06-30 | 419902 |
| 2024-09-30 | 258613 |
| 2024-12-31 | 329446 |
| 2025-03-31 | 325849 |
| 2025-06-30 | 430043 |
| 2025-09-30 | 489325 |
| 2025-12-31 | 378989 |
| 2026-03-31 | 322643 |
| 2026-06-30 | 656098 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q2 2026 | Added | 61,032 | +8,570 (16.3%) | < 0.01% | $656,098 | 2026-08-06 | |
| Q1 2026 | Added | 52,462 | +3,243 (6.6%) | < 0.01% | $322,643 | 2026-05-05 | |
| Q4 2025 | Reduced | 49,219 | -3,059 (-5.9%) | < 0.01% | $378,989 | 2026-02-10 | |
| Q3 2025 | Added | 52,278 | +466 (0.9%) | < 0.01% | $489,325 | 2025-11-03 | |
| Q2 2025 | Reduced | 51,812 | -1,694 (-3.2%) | < 0.01% | $430,043 | 2025-08-05 | |
| Q1 2025 | Added | 53,506 | +1,378 (2.6%) | < 0.01% | $325,849 | 2025-04-29 | |
| Q4 2024 | Added | 52,128 | +405 (0.8%) | < 0.01% | $329,446 | 2025-02-04 | |
| Q3 2024 | Reduced | 51,723 | -17,001 (-24.7%) | < 0.01% | $258,613 | 2024-11-12 | |
| Q2 2024 | Added | 68,724 | +20,602 (42.8%) | < 0.01% | $419,902 | 2024-07-25 | |
| Q1 2024 | Added | 48,122 | +2,129 (4.6%) | < 0.01% | $535,112 | 2024-04-25 | |
| Q4 2023 | Reduced | 45,993 | -339 (-0.7%) | < 0.01% | $516,038 | 2024-01-29 | |
| Q3 2023 | Added | 46,332 | +1,090 (2.4%) | < 0.01% | $347,950 | 2023-10-24 | |
| Q2 2023 | New | 45,242 | +45,242 (0.0%) | < 0.01% | $399,483 | 2023-08-03 | |
|
Five years are shown. A free account unlocks the complete reported history.
Unlock full history
|
|||||||
Who else reported the position
81 managers reported FENNEC PHARMACEUTICALS INC for Q2 2024.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| Southpoint Capital Advisors LP | Unchanged | 4,077,214 | 0 | 0.62% | $24,911,778 | 28 qtrs |
| Sonic GP LLC | Unchanged | 2,407,357 | 0 | 30.37% | $14,708,951 | 7 qtrs |
| DG Capital Management LLC | Added | 1,634,811 | +123,148 | 3.85% | $9,988,695 | 13 qtrs |
| Solas Capital Management LLC | Added | 1,340,000 | +229,767 | 4.48% | $8,187,400 | 21 qtrs |
| BlackRock Inc | Added | 1,187,242 | +259,776 | < 0.01% | $7,254,049 | 25 qtrs |
| VANGUARD GROUP INC | Added | 1,026,654 | +13,028 | < 0.01% | $6,272,856 | 5 qtrs |
| HARBERT FUND ADVISORS INC | Unchanged | 466,869 | 0 | 2.03% | $2,852,570 | 13 qtrs |
| STATE STREET CORPORATION | Added | 321,206 | +17,687 | < 0.01% | $1,962,569 | 5 qtrs |
| GEODE CAPITAL MANAGEMENT LLC | Added | 301,578 | +81,824 | < 0.01% | $1,842,640 | 17 qtrs |
| GENDELL JEFFREY L | Reduced | 283,365 | -19,113 | 0.06% | $1,731,360 | 7 qtrs |
Filing details and methodology As reported
- Report period
- June 30, 2024
- Filed
- July 25, 2024
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
- Sole
- 56,967
- Shared
- 0
- None
- 11,757
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.